

# Giuseppe Losurdo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/975446/publications.pdf>

Version: 2024-02-01

93  
papers

1,809  
citations

257357

24  
h-index

330025

37  
g-index

93  
all docs

93  
docs citations

93  
times ranked

2575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. <i>Antibiotics</i> , 2022, 11, 78.	1.5	4
2	Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). <i>Journal of Clinical Medicine</i> , 2022, 11, 1658.	1.0	13
3	Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4461.	1.8	15
4	Assessment of body composition: Intrinsic methodological limitations and statistical pitfalls. <i>Nutrition</i> , 2022, 102, 111736.	1.1	4
5	Helicobacter pylori Antibiotic Resistance: Stewardship, Tailored Therapies, and Future Perspectives. <i>Gastroenterology</i> , 2021, 161, 1071-1072.	0.6	5
6	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
7	Intraepithelial lymphocytes: bystanders or causative factors in functional gastrointestinal disorders?. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1620-1621.	4.8	5
8	Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives. <i>Current Oncology</i> , 2021, 28, 4256-4263.	0.9	9
9	May Antitransglutaminase Levels Predict Severity of Duodenal Lesions in Adults with Celiac Disease?. <i>Medicina (Lithuania)</i> , 2021, 57, 1212.	0.8	2
10	Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 201-207.	0.8	8
11	Serologic diagnosis of celiac disease: May it be suitable for adults?. <i>World Journal of Gastroenterology</i> , 2021, 27, 7233-7239.	1.4	5
12	Liver involvement in inflammatory bowel disease: What should the clinician know?. <i>World Journal of Hepatology</i> , 2021, 13, 1534-1551.	0.8	6
13	Novel frontiers of agents for bowel cleansing for colonoscopy. <i>World Journal of Gastroenterology</i> , 2021, 27, 7748-7770.	1.4	10
14	An uncommon etiology of pancreatitis after endoscopic ultrasound-guided fine needle aspiration. <i>Endoscopy</i> , 2020, 52, E106-E107.	1.0	0
15	What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors?. <i>Gastroenterology</i> , 2020, 158, 1175.	0.6	6
16	Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 16-28.	0.8	38
17	Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. <i>Antibiotics</i> , 2020, 9, 723.	1.5	17
18	Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. <i>Pathogens</i> , 2020, 9, 870.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Human Leukocyte Antigen (HLA) Haplotype Does Not Influence the Inflammatory Pattern of Duodenal Lymphocytosis Linked to Irritable Bowel Syndrome. <i>Medicina (Lithuania)</i> , 2020, 56, 660.	0.8	0
20	Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. <i>Diagnostics</i> , 2020, 10, 1037.	1.3	2
21	The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3531.	1.8	37
22	The Puzzle of Coccoid Forms of <i>Helicobacter pylori</i> : Beyond Basic Science. <i>Antibiotics</i> , 2020, 9, 293.	1.5	30
23	Might <i>helicobacter pylori</i> play a role in allergic or cross-reaction related disorders?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 643-646.	1.4	5
24	Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. <i>Diagnostics</i> , 2020, 10, 213.	1.3	3
25	Endoscopic stenting for colorectal cancer obstruction as a bridge-to-surgery strategy. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13252.	1.7	3
26	Curcumin and Colorectal Cancer: From Basic to Clinical Evidences. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2364.	1.8	133
27	Quadruple Rescue erapy aer First and Second Line Failure for <i>Helicobacter pylori</i> Treatment: Comparison between Two Tetracycline-Based Regimens. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 367-370.	0.5	45
28	Does Infliximab Short Infusion have a Beneficial Impact on the Quality of Life in Patients with Inflammatory Bowel Diseases? A Single Centre Prospective Evaluation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 165-170.	0.5	17
29	<i>Escherichia coli</i> Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 499-505.	0.5	77
30	Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model. <i>World Journal of Gastroenterology</i> , 2020, 26, 1601-1612.	1.4	10
31	Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. <i>World Journal of Gastroenterology</i> , 2020, 26, 7528-7537.	1.4	16
32	OC.10.3 SILYMARIN, BOSWELLIC ACID, CURCUMIN AND MALTODEXTRIN ENRICHED DIETETIC FORMULATION REDUCES THE GROWTH OF INHERITED INTESTINAL POLYPS IN AN ANIMAL MODEL. <i>Digestive and Liver Disease</i> , 2019, 51, e104.	0.4	1
33	The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy. <i>Medicina (Lithuania)</i> , 2019, 55, 59.	0.8	13
34	Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 2524-2538.	1.4	21
35	Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectiveness. <i>World Journal of Gastroenterology</i> , 2019, 25, 5097-5104.	1.4	45
36	Letter: dose-response analysis revealed closer relationship between obesity and perioperative outcomes in patients after liver transplantation—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 312-313.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1589-1596.	0.9	58
38	Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 704-714.	1.9	46
39	Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population. <i>Annals of Gastroenterology</i> , 2018, 31, 469-473.	0.4	24
40	P797 Costs distribution of conventional or biologic drugs in ulcerative colitis and Crohn's disease: A single outpatient centre experience. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S514-S515.	0.6	0
41	Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study. <i>Nutrients</i> , 2018, 10, 2001.	1.7	10
42	Probiotic monotherapy and <i>Helicobacter pylori</i> eradication: A systematic review with pooled-data analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 139-149.	1.4	78
43	Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. <i>World Journal of Gastroenterology</i> , 2018, 24, 1521-1530.	1.4	59
44	Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 15-20.	0.9	12
45	Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model. <i>Carcinogenesis</i> , 2018, 39, 1274-1282.	1.3	23
46	Novel steps forward in the histopathology of non-celiac gluten sensitivity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 523-523.	1.4	4
47	A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal. <i>Current Drug Safety</i> , 2018, 13, 221-223.	0.3	7
48	Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2018, 11, 203-208.	0.6	9
49	Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled data analysis. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13028.	1.6	35
50	Systematic review with meta-analysis: postoperative complications and mortality risk in liver transplant candidates with obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 236-245.	1.9	43
51	Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. <i>Cell Death and Disease</i> , 2017, 8, e3040-e3040.	2.7	7
52	Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 460-461.	1.9	2
53	T Helper Lymphocyte and Mast Cell Immunohistochemical Pattern in Nonceliac Gluten Sensitivity. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	0.7	19
54	Noninvasive molecular analysis of <i>Helicobacter pylori</i> : Is it time for tailored first-line therapy?. <i>World Journal of Gastroenterology</i> , 2017, 23, 2453.	1.4	37

#	ARTICLE	IF	CITATIONS
55	Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?. <i>Annals of Gastroenterology</i> , 2017, 30, 380-392.	0.4	23
56	Sequential Therapy For <i>Helicobacter pylori</i> in Elderly Patients: Effectiveness, Safety and Predictors of Success. <i>Letters in Drug Design and Discovery</i> , 2017, 14, 500-505.	0.4	0
57	Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. <i>World Journal of Gastroenterology</i> , 2016, 22, 4802.	1.4	49
58	Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 373-377.	0.7	10
59	<i>Helicobacter pylori</i> DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1429-1432.	0.6	27
60	Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for <i>Helicobacter pylori</i> treatment?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 844-845.	1.9	5
61	<i>Helicobacter pylori</i> , liver cirrhosis, and portal hypertension: an updated appraisal. <i>Immunopharmacology and Immunotoxicology</i> , 2016, 38, 408-413.	1.1	8
62	The Interaction Between Celiac Disease and Intestinal Microbiota. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S145-S147.	1.1	26
63	P.16.15 FAMILIAL ADENOMATOUS POLYPOSIS SMALL BOWEL SURVEILLANCE: COULD INDICATORS FOR VIDEO-CAPSULE ENDOSCOPY BE ASCERTAINED?. <i>Digestive and Liver Disease</i> , 2016, 48, e211.	0.4	1
64	Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for <i>Helicobacter pylori</i> eradication: how should rifabutin be managed in rescue regimens?. <i>United European Gastroenterology Journal</i> , 2016, 4, 474-475.	1.6	6
65	Acute pancreatitis in elderly patients: A retrospective evaluation at hospital admission. <i>European Journal of Internal Medicine</i> , 2016, 30, 88-93.	1.0	23
66	Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 143-151.	0.6	20
67	Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 277-280.	0.6	30
68	Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 253-255.	0.6	13
69	Pathological and Clinical Correlation between Celiac Disease and <i>Helicobacter Pylori</i> Infection; a Review of Controversial Reports. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 85-92.	0.2	10
70	Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?. <i>World Journal of Gastroenterology</i> , 2016, 22, 3202.	1.4	7
71	May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?. <i>World Journal of Gastroenterology</i> , 2016, 22, 8017.	1.4	17
72	Role of concomitant therapy for <i>Helicobacter pylori</i> eradication: A technical note. <i>World Journal of Gastroenterology</i> , 2016, 22, 8638.	1.4	2

#	ARTICLE	IF	CITATIONS
73	A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of <i>Helicobacter Pylori</i> infection: A further confirmation of "Geographic Weight". <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 77.	0.5	3
74	Familial adenomatous polyposis small bowel surveillance: could indicators for video-capsule endoscopy be ascertained?. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 272-3.	2.2	1
75	Letter: portal vein obstruction " which subset of patients could benefit the most?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 909-909.	1.9	1
76	Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg?. <i>Nutrients</i> , 2015, 7, 7486-7504.	1.7	31
77	The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1002-1010.	0.6	12
78	Letter: <i>Helicobacter</i> -negative gastritis - a distinct condition?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 597-598.	1.9	5
79	Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1302-1302.	1.9	2
80	Sequential vs. prolonged 14-day triple therapy for <i>Helicobacter pylori</i> eradication: the meta-analysis may be influenced by "geographical weighting"™. <i>International Journal of Clinical Practice</i> , 2015, 69, 1112-1120.	0.8	21
81	Detection of <i>Helicobacter pylori</i> DNA sequences in gastric biopsy samples to refine the diagnosis and therapy. <i>Journal of Medical Microbiology</i> , 2015, 64, 788-789.	0.7	10
82	Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up. <i>World Journal of Gastroenterology</i> , 2015, 21, 7545.	1.4	25
83	Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 289-92.	0.7	22
84	Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 379.	0.5	9
85	Seronegative celiac disease: where is the specific setting?. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015, 8, 110-6.	0.6	32
86	Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?. <i>Scientific World Journal</i> , The, 2014, 2014, 1-6.	0.8	6
87	Ulcerative colitis: From inflammation to cancer. Do estrogen receptors have a role?. <i>World Journal of Gastroenterology</i> , 2014, 20, 11496.	1.4	31
88	<i>Helicobacter pylori</i> and Nonmalignant Diseases. <i>Helicobacter</i> , 2014, 19, 27-31.	1.6	25
89	Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?. <i>Current Drug Safety</i> , 2014, 9, 196-204.	0.3	13
90	Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 17686.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 550.	0.5	54
92	How antibiotic resistances could change <i>Helicobacter pylori</i> treatment: A matter of geography?. World Journal of Gastroenterology, 2013, 19, 8168.	1.4	94
93	Primary clarithromycin resistance to <i>Helicobacter pylori</i> : Is this the main reason for triple therapy failure?. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 43.	0.5	34